JP6795399B2 - 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 - Google Patents

改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 Download PDF

Info

Publication number
JP6795399B2
JP6795399B2 JP2016559573A JP2016559573A JP6795399B2 JP 6795399 B2 JP6795399 B2 JP 6795399B2 JP 2016559573 A JP2016559573 A JP 2016559573A JP 2016559573 A JP2016559573 A JP 2016559573A JP 6795399 B2 JP6795399 B2 JP 6795399B2
Authority
JP
Japan
Prior art keywords
cells
cell
cd16a
bike
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016559573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511135A (ja
JP2017511135A5 (enExample
Inventor
ケネス ウォルチェック ブルース
ケネス ウォルチェック ブルース
サミュエル コーフマン ダン
サミュエル コーフマン ダン
ウー ジエンミーン
ウー ジエンミーン
ヤーウー ジーン
ヤーウー ジーン
ジェンヤー ニー
ジェンヤー ニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2017511135A publication Critical patent/JP2017511135A/ja
Publication of JP2017511135A5 publication Critical patent/JP2017511135A5/ja
Application granted granted Critical
Publication of JP6795399B2 publication Critical patent/JP6795399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2016559573A 2014-03-28 2015-03-27 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法 Active JP6795399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971996P 2014-03-28 2014-03-28
US61/971,996 2014-03-28
PCT/US2015/022998 WO2015148926A1 (en) 2014-03-28 2015-03-27 Polypeptides, cells, and methods involving engineered cd16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020188582A Division JP7091423B2 (ja) 2014-03-28 2020-11-12 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法

Publications (3)

Publication Number Publication Date
JP2017511135A JP2017511135A (ja) 2017-04-20
JP2017511135A5 JP2017511135A5 (enExample) 2018-05-17
JP6795399B2 true JP6795399B2 (ja) 2020-12-02

Family

ID=52829414

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016559573A Active JP6795399B2 (ja) 2014-03-28 2015-03-27 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法
JP2020188582A Active JP7091423B2 (ja) 2014-03-28 2020-11-12 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法
JP2022096496A Active JP7575426B2 (ja) 2014-03-28 2022-06-15 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法
JP2024182081A Pending JP2025004257A (ja) 2014-03-28 2024-10-17 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020188582A Active JP7091423B2 (ja) 2014-03-28 2020-11-12 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法
JP2022096496A Active JP7575426B2 (ja) 2014-03-28 2022-06-15 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法
JP2024182081A Pending JP2025004257A (ja) 2014-03-28 2024-10-17 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法

Country Status (9)

Country Link
US (4) US10464989B2 (enExample)
EP (2) EP3122769B1 (enExample)
JP (4) JP6795399B2 (enExample)
CN (2) CN113699159A (enExample)
AU (3) AU2015235852B2 (enExample)
CA (1) CA2944199C (enExample)
ES (1) ES2941679T3 (enExample)
PT (1) PT3122769T (enExample)
WO (1) WO2015148926A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3122769B1 (en) 2014-03-28 2023-02-22 Regents of the University of Minnesota Polypeptides, cells, and methods involving engineered cd16
EP3250680A4 (en) 2015-01-26 2018-12-05 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
AU2016349504B2 (en) * 2015-11-04 2023-02-09 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
SG11201803145RA (en) 2015-11-04 2018-05-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
US20180360881A1 (en) * 2015-12-09 2018-12-20 Nant Holdings Ip, Llc Compositions and Methods for Treatment of Her2 Positive Metastatic Breast Cancer
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
IL310925A (en) 2016-01-15 2024-04-01 American Gene Tech Int Inc Methods and compositons for the activation of gamma-delta t-cells
WO2017156311A2 (en) 2016-03-09 2017-09-14 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
AU2017386790A1 (en) * 2016-12-30 2019-07-18 Celularity Inc. Genetically modified natural killer cells
CN110770338A (zh) 2017-06-16 2020-02-07 美国基因技术国际有限公司 由人γ-δ T细胞激活肿瘤细胞毒性的方法和组合物
AU2018355462B9 (en) * 2017-10-26 2022-04-28 Regents Of The University Of Minnesota Recombinant immune cells, methods of making, and methods of use
IL309585B2 (en) 2017-12-22 2025-03-01 Fate Therapeutics Inc Enhanced immune effector cells and use thereof
JP7273421B2 (ja) * 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
EP3775228A4 (en) 2018-03-29 2022-02-23 Fate Therapeutics, Inc. ENHANCED IMMUNE EFFECTIVE CELLS AND THEIR USE
JP2022506515A (ja) 2018-11-05 2022-01-17 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド 制御性ｒｎａを発現させるためのベクターシステム
WO2020117526A1 (en) 2018-12-02 2020-06-11 Fate Therapeutics, Inc. IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
JP2022541441A (ja) 2019-07-17 2022-09-26 フェイト セラピューティクス，インコーポレイテッド 免疫エフェクター細胞操作およびその使用
WO2021022229A1 (en) * 2019-07-31 2021-02-04 Celularity Inc. Populations of natural killer cells comprising a cleavage resistant cd16
WO2021113849A1 (en) * 2019-12-05 2021-06-10 Celularity Inc. Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16
CA3182852A1 (en) 2020-06-19 2021-12-23 Fate Therapeutics, Inc. Combining ipsc-derived effector cell types for immunotherapy use
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
KR20230147060A (ko) * 2021-01-21 2023-10-20 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 조작된 nk 세포 및 암 치료 방법
KR102894135B1 (ko) * 2021-09-29 2025-12-04 카오티에스 주식회사 신규한 재조합 Fc 수용체 및 이를 포함하는 세포
CN116948012B (zh) * 2022-04-13 2024-07-26 星奕昂(上海)生物科技有限公司 增强细胞功能的cd16抗剪切突变体
CN114774469B (zh) * 2022-06-22 2022-11-08 南京艾尔普再生医学科技有限公司 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物
CN119907854A (zh) * 2022-09-29 2025-04-29 上海先博生物科技有限公司 工程改造的免疫效应细胞及其组合物和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US121788A (en) * 1871-12-12 Improvement in match-boxes
US6444789B1 (en) 1995-05-03 2002-09-03 Applied Research Systems Ars Holding N.V. CD16-II variants
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2550998A1 (en) 2003-12-22 2005-07-14 Chiron Corporation Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
EP2801583B1 (en) * 2004-07-10 2018-04-25 Fox Chase Cancer Center Genetically modified human natural killer cell lines
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
CN101627054A (zh) * 2005-07-11 2010-01-13 马克罗基因公司 用人源化抗cd16a抗体治疗自身免疫疾病的方法
US20080003225A1 (en) * 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
US8440811B2 (en) * 2008-10-03 2013-05-14 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University DNA nanostructures that promote cell-cell interaction and use thereof
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
EP3122769B1 (en) 2014-03-28 2023-02-22 Regents of the University of Minnesota Polypeptides, cells, and methods involving engineered cd16

Also Published As

Publication number Publication date
US11370825B2 (en) 2022-06-28
AU2022204134B2 (en) 2024-11-28
JP2017511135A (ja) 2017-04-20
PT3122769T (pt) 2023-04-24
JP2025004257A (ja) 2025-01-14
US20200017570A1 (en) 2020-01-16
CN106715467B (zh) 2021-07-27
US12098182B2 (en) 2024-09-24
JP2022121484A (ja) 2022-08-19
CN106715467A (zh) 2017-05-24
US20210332103A1 (en) 2021-10-28
US20170174743A1 (en) 2017-06-22
EP3122769B1 (en) 2023-02-22
JP7091423B2 (ja) 2022-06-27
AU2019250155A1 (en) 2019-10-31
EP4227318A1 (en) 2023-08-16
AU2019250155B2 (en) 2022-03-17
WO2015148926A1 (en) 2015-10-01
JP7575426B2 (ja) 2024-10-29
AU2015235852B2 (en) 2019-08-15
US10464989B2 (en) 2019-11-05
CN113699159A (zh) 2021-11-26
US20240417441A1 (en) 2024-12-19
EP3122769A1 (en) 2017-02-01
JP2021035390A (ja) 2021-03-04
WO2015148926A9 (en) 2016-11-10
AU2015235852A1 (en) 2016-10-20
ES2941679T3 (es) 2023-05-24
AU2022204134A1 (en) 2022-06-30
CA2944199A1 (en) 2015-10-01
CA2944199C (en) 2023-08-15

Similar Documents

Publication Publication Date Title
JP7091423B2 (ja) 改変ｃｄ１６が関係するポリペプチド、細胞、及び方法
JP2021516996A (ja) 生物学的に関連する直交サイトカイン／受容体対
US20200157237A1 (en) Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof
JP2022078246A (ja) 組換え免疫細胞、作製方法、および使用方法
JP2020511131A (ja) 臨床のための、改変されたＮＫ−９２ ｈａＮＫ００３細胞
CN107523546A (zh) 一种高效稳定表达抗体的nk细胞及其用途
US12345711B2 (en) Methods to determine antibody activity in tumor samples
KR20230017840A (ko) 조작된 인터루킨-10 폴리펩타이드 및 이의 용도
CN113164521A (zh) 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
WO2017219933A1 (zh) 一种高效稳定表达抗体的t细胞及其用途
HK40101335A (en) Polypeptides, cells, and methods involving engineered cd16
HK40064550A (en) Polypeptides, cells, and methods involving engineered cd16
HK1237796B (zh) 涉及经工程改造的cd16的多肽、细胞和方法
HK1237796A1 (en) Polypeptides, cells, and methods involving engineered cd16
HK40025672A (en) Recombinant immune cells, methods of making, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201013

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201112

R150 Certificate of patent or registration of utility model

Ref document number: 6795399

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250